Hatleberg, CI;
Ryom, L;
Monforte, AD;
Fontas, E;
Reiss, P;
Kirk, O;
El-Sadr, W;
... Sabin, C; + view all
(2018)
Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.
HIV Medicine
, 19
(9)
pp. 605-618.
10.1111/hiv.12639.
Preview |
Text
Sabin Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons_clean versionAPR16.pdf - Accepted Version Download (881kB) | Preview |
Abstract
Objectives Previous studies have suggested that hypertension in HIV‐positive individuals is associated primarily with traditional risk factors such as older age, diabetes and dyslipidaemia. However, controversy remains as to whether exposure to antiretroviral (ARV) drugs poses additional risk, and we investigated this question in the Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) cohort. Methods The incidence of hypertension [systolic blood pressure (BP) > 140 and/or diastolic BP > 90 mmHg and/or initiation of antihypertensive treatment] was determined overall and in strata defined by demographic, metabolic and HIV‐related factors, including cumulative exposure to each individual ARV drug. Predictors of hypertension were identified using uni‐ and multivariable Poisson regression models. Results Of 33 278 included persons, 7636 (22.9%) developed hypertension over 223 149 person‐years (PY) [incidence rate: 3.42 (95% confidence interval (CI) 3.35–3.50) per 100 PY]. In univariable analyses, cumulative exposure to most ARV drugs was associated with an increased risk of hypertension. After adjustment for demographic, metabolic and HIV‐related factors, only associations for nevirapine [rate ratio 1.07 (95% CI: 1.04–1.13) per 5 years] and indinavir/ritonavir [rate ratio 1.12 (95% CI: 1.04–1.20) per 5 years] remained statistically significant, although effects were small. The strongest independent predictors of hypertension were male gender, older age, black African ethnicity, diabetes, dyslipidaemia, use of lipid‐lowering drugs, high body mass index (BMI), renal impairment and a low CD4 count. Conclusions We did not find evidence for any strong independent association between exposure to any of the individual ARV drugs and the risk of hypertension. Findings provide reassurance that screening policies and preventative measures for hypertension in HIV‐positive persons should follow algorithms used for the general population.
| Type: | Article |
|---|---|
| Title: | Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1111/hiv.12639 |
| Publisher version: | https://doi.org/10.1111/hiv.12639 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Infectious Diseases, antiretroviral therapy, cardiovascular disease, HIV, hypertension, IMMUNODEFICIENCY-VIRUS-INFECTION, MYOCARDIAL-INFARCTION RATES, CARDIOVASCULAR RISK-FACTORS, INCREASED BLOOD-PRESSURE, CORONARY-HEART-DISEASE, METABOLIC SYNDROME, UNINFECTED INDIVIDUALS, GENERAL-POPULATION, DIABETES-MELLITUS, AORTIC STIFFNESS |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health > Infection and Population Health |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10058632 |
Archive Staff Only
 |
View Item |
